Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. tir-c

TIR-C SIGNED

NEXT GENERATION TOPICAL MEDICATION TO TREAT IMMUNE RESPONSES IN ATOPIC DERMATITIS – THE MOST COMMON CAUSE OF ECZEMA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TIR-C project word cloud

Explore the words cloud of the TIR-C project. It provides you a very rough idea of what is the project "TIR-C" about.

economic    manufacturing    works    administrated    regulatory    unsuitable    pharma    intravenously    interfere    vital    deprivation    dermatology    freedom    readiness    skin    poses    plan    trials    societies    extremely    approvals    inflammation    unmet    kols    relives    escalation    blockbuster    itch    therapy    steroids    defences    ab    rate    formulation    clinical    local    treatment    children    topical    atopic    expenditures    enormous    excellent    dermatitis    pricing    unresolved    damage    steroid    immune    clinicians    mild    sufferers    psychological    burden    costly    safe    mind    market    commercialisation    biologics    symptoms    conduct    validate    tir    anti    diabetes    lesions    self    action    communicated    group    patients    operate    infected    eliminate    contain    life    profile    preparations    ad    consequently    patient    feasibility    80    drafted    quality    safety    confirm    consistently    productivity    entirely    cro    cream    symptom    severe    mechanism    tirmed    moderate    survey    health    disease    affordable    iia    sleep    water    contract    prevent    persons   

Project "TIR-C" data sheet

The following table provides information about the project.

Coordinator		 TIRMED PHARMA AB 

Organization address
address: SPETS ALVIKSVAGEN 1
city: BROMMA
postcode: 16753
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TIRMED PHARMA AB SE (BROMMA) coordinator 50˙000.00

Map

 Project objective

TIRmed pharma AB has developed a non-steroid cream that relives itch in Atopic Dermatitis (AD). Itch is an enormous, unresolved symptom in AD, induced by inflammation and skin damage. AD poses a significant burden on societies and patients’ quality of life due to itch, infected lesions, sleep deprivation, and consequently productivity loss, psychological health and treatment-associated expenditures. Persons affected by AD consistently rate AD management to be comparable to diabetes management. Our TIR-C cream doesn’t contain steroids and works through an entirely novel mechanism of action. The therapy has been developed with the largest patient group in mind; children. TIR-C has the potential to become a blockbuster in AD management as it has an excellent safety profile, is very affordable, is easy to self-apply (water-based), doesn’t interfere with vital immune defences and has the potential to prevent disease escalation. We target mild-to-moderate symptoms (80% of all AD sufferers), aiming to eliminate the need for intravenously administrated biologics. Biologics are not only extremely costly, but also associated with severe side effects, making them unsuitable for children. The unmet need for safe, topical anti-itch-treatment in persons with mild-to-moderate AD has been clearly communicated by leading contract research organizations, KOLs and clinicians within dermatology. TIR-C is at Technology Readiness Level 4 with established manufacturing and formulation processes and a clinical development plan drafted in collaboration with a leading CRO in dermatology. The proposed feasibility study will advance preparations for commercialisation by allowing us to confirm regulatory requirements needed for market approvals, validate pricing through a health-economic survey in the EU, identify a local CRO to conduct the planned phase I/IIa clinical trials and confirm Freedom to Operate.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIR-C" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TIR-C" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More